<DOC>
	<DOCNO>NCT02158858</DOCNO>
	<brief_summary>Open-label , sequential dose escalation expansion study CPI-0610 patient previously treat Acute Leukemia , Myelodysplastic Syndrome , Myelodysplastic/Myeloproliferative Neoplasms , Myelofribrosis . CPI-0610 small molecule inhibitor bromodomain extra-terminal ( BET ) proteins .</brief_summary>
	<brief_title>A Phase 1 Study Evaluating CPI-0610 Patients With Acute Leukemia , Myelodysplastic Syndrome , Myelodysplastic/Myeloproliferative Neoplasms , Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Adult ( age ≥ 18 year ) Histologically cytologically confirm diagnosis one follow hematologic malignancy : AML , ALL , acute undifferentiated biphenotypic leukemia , CML blast crisis , MDS MDS/MPN , Myelofribrosis ECOG performance status ≤2 . Adequate hematological , renal , hepatic , coagulation laboratory assessment Patients must give write informed consent participate study performance studyrelated procedure . Newly diagnose acute leukemia treat standard induction chemotherapeutic regimen another antileukemic agent Relapsed refractory acute leukemia , additional induction chemotherapy consider potential clinical benefit Acute leukemia relapse le 6 month follow allogeneic stem cell transplantation CML blast crisis previously treat one bcrabl TKI Very low low risk MDS without previous treatment Central nervous system ( CNS ) ( e.g. , leptomeningeal ) involvement leukemia Current infection HIV , Hepatitis B Hepatitis C Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption CPI0610 , include unresolved nausea , vomit , diarrhea CTCAE grade &gt; 1 Impaired cardiac function clinically significant cardiac disease , include follow : Acute myocardial infarction angina pectoris ≤ 6 month prior start study drug Serum cardiac troponin ( cTn ) level ≥ 99 % percentile upper reference limit QTcF &gt; 470 msec screen ECG Left ventricular ejection fraction ( LVEF ) &lt; 50 % Uncontrolled cardiac arrhythmia ( patient ratecontrolled atrial fibrillation exclude . ) Any concurrent severe and/or uncontrolled concomitant medical condition could compromise participation study ( e.g. , clinically significant pulmonary disease , clinically significant neurological disorder , active uncontrolled infection ) Systemic anticancer treatment small molecule therapeutic hydroxyurea radiotherapy le 2 week first dose CPI0610 Administration therapeutic antibody le 4 week first dose CPI0610 . A minimum 2week period last treatment therapeutic antibody first dose CPI0610 may permit patient rapidly progressive disease , follow discussion medical monitor Treatment investigational small molecule le 2 week first dose CPI0610 . In addition , first dose CPI0610 occur period equal great 5 halflives small molecule investigational agent elapse Treatment medication know strong inhibitor inducer CYP450 enzymes Treatment medication know carry risk Torsades de Pointes Immunosuppressive treatment discontinue prior study entry duration study . Oral prednisone dose 10 mg less per day allow , oral corticosteroid give glucocorticoidequivalent dos . Topical , nasal inhaled corticosteroid also allow Pregnant lactate woman Women childbearing potential men reproductive potential , unwilling use adequate contraception study therapy 3 month thereafter Patients unwilling unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Oncology</keyword>
	<keyword>BET Inhibitor</keyword>
</DOC>